Edition:
United Kingdom

NuCana PLC (NCNA.OQ)

NCNA.OQ on NASDAQ Stock Exchange Global Select Market

11.13USD
8:59pm GMT
Change (% chg)

$-0.14 (-1.24%)
Prev Close
$11.27
Open
$11.09
Day's High
$11.13
Day's Low
$10.68
Volume
11,605
Avg. Vol
--
52-wk High
$19.95
52-wk Low
$9.71

Summary

Name Age Since Current Position

Christopher Wood

70 Chairman of the Board, Co-Founder & Chief Medical Officer

Hugh Griffith

48 Chief Executive Officer, Founder, Director

Donald Munoz

2015 Chief Financial Officer

Martin Mellish

Non-Executive Director

Rafaele Tordjman

2011 Non-Executive Director

Biographies

Name Description

Christopher Wood

Dr. Christopher (Chris) B. Wood, M.D., is Chairman of the Board, Co-Founder & Chief Medical Officer of NuCana BioMed, Ltd. Christopher Wood is our co-founder and has served as a member of our board of directors since our founding and as our Chairman since 2008. Dr. Wood also currently serves as chairman of several biopharmaceutical or biotechnology companies including: Edixomed Limited, MedAnnex Limited and OncoBioPharm Limited. In addition, he is a director of MiNA Therapeutics Limited. Prior to joining our board of directors, Dr. Wood was a co-founder of Bioenvision, Inc., a biopharmaceutical company, and served as its Chairman and Chief Executive Officer until 2007, when it was acquired by Genzyme Corporation (now Sanofi). Previously Dr. Wood was chairman of the board and Chief Executive of Eurobiotech, Inc., co-founder and director of Genethics Ltd until it was acquired by Proteus International plc. Dr. Wood co-founded and served as chairman of Medirace Ltd., a biotechnology company, which later became Medeva PLC and was acquired by Celltech Group PLC (now UCB). From 1979 to 1991, Dr. Wood was a surgical oncologist at The Royal Postgraduate Medical School and a consultant surgeon at Hammersmith Hospital, both in London, England. Dr. Wood is an honorary Professor at Imperial College London, a Fellow of the Royal College of Surgeons of Edinburgh and a Fellow of the Learned Society of Wales. Dr. Wood received an M.D. from the University of Wales School of Medicine.

Hugh Griffith

Mr. Hugh S. Griffith is Chief Executive Officer, Founder, Director of NuCana BioMed, Ltd. Griffith is our founder and has served as our Chief Executive Officer and as a member of our board of directors since our operations began in 2008. In addition, he currently serves as a non-executive director of EdixoMed Limited and MedAnnex Limited, biotech companies which he co-founded in 2009. He also serves as director of Alida Capital International, a biotech business angel syndicate that he formed in 2009. Prior to founding NuCana, Mr. Griffith was Chief Operating Officer of Bioenvision, Inc., a biopharmaceutical company, from 2002 until 2007, when it was acquired by Genzyme Corporation (now Sanofi). Before that, Mr. Griffith held several senior commercial positions at Quantanova Limited (a biopharmaceutical company), Abbott Laboratories (now AbbVie Inc.) and Warner-Lambert Company (now Pfizer Inc.). He currently serves on the advisory board of the Scottish Lifesciences Association. Mr. Griffith received an M.B.A. from Cardiff Business School and a B.Sc. Honours in Biology from the University of Stirling.

Donald Munoz

Mr. Donald Munoz is Chief Financial Officer of the Company. Prior to joining NuCana, Mr. Munoz served as Group Chief Financial Officer of NOXXON Pharma AG (now NOXXON Pharma N.V.), a biopharmaceutical company. Before that, he was Head of Investment Banking at Summer Street Research Partners, an investment banking and institutional securities firm focused exclusively on healthcare, from 2012 to 2014. Mr. Munoz previously served as a Managing Director leading the medical technology investment banking franchises at Cowen and Company, LLC from 2009 to 2011 and Leerink Partners LLC from 2005 to 2009. Prior to that, he spent approximately ten years in the healthcare investment banking group at Alex. Brown & Sons and its successor, Deutsche Bank Securities. Mr. Munoz received an M.B.A. in Finance and Accounting from Columbia Business School and a B.A. from Dartmouth College.

Martin Mellish

Mr. Martin Mellish is a Non-Executive Director of NuCana BioMed, Ltd. Mellish has served as a member of our board of directors since December 2009. Since 1994, Mr. Mellish has served as the Executive Director of Aspen Advisory Services Ltd., a London-based private investment office overseeing private and publicly traded investments in North America, Europe and Asia. Mr. Mellish also currently serves as a non-executive director of Kensington Green (Management) Limited, a real estate management company, Levitronix Technologies LLC, a technology company, Alturki Holding, an industrial investment and development holding company, Livercyte Limited, a biotechnology company, and Omnicyte Limited, a biotechnology company. From 1992 to 1994, Mr. Mellish pursued studies at the Massachusetts Institute of Technology. From 1984 to 1992, he was controller and subsequently Chief Financial Officer of Alturki Holding. Prior to that, Mr. Mellish trained at Price Waterhouse Coopers. He was awarded an SM (Management) from the Massachusetts Institute of Technology and an M.Sc. (Accounting) from Northeastern University.

Rafaele Tordjman

Dr. Rafaele Tordjman is Non-Executive Director of the Company. Tordjman has served as a member of our board of directors since November 2011. Dr. Tordjman served as a Managing Partner at Sofinnova Partners, an independent venture capital firm based in Paris, where she specialized in life sciences investments. She joined Sofinnova Partners in 2001 and from 2011 to 2017. Dr. Tordjman currently serves as a director of ObsEva SA and Lysogene, two a biopharmaceutical companies, and has previously served as a director of several biopharmaceutical or biotechnology companies, including: Ascendis Pharma A/S, DBV Technologies S.A., Medtronic CoreValve LLC and Flexion Therapeutics, Inc. Previously, Dr. Tordjman was a research scientist at the Institut National de la Santé et de la Recherche Médicale (INSERM) in Cochin Hospital, Paris, France. Before joining INSERM, Dr. Tordjman was a medical doctor specializing in clinical hematology and internal medicine. Dr. Tordjman received a Ph.D. with high honors in hematopoiesis and angiogenesis, and a post-doctoral fellowship in immunology, from the University Paris VII. Dr. Tordjman received an M.D. and fellowship in hematology and internal medicine from the Paris University Hospitals.

Basic Compensation

Options Compensation